Pre-market Hot Trades in US Stocks
Applied Digital is down 3.57% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 5, Applied Digital completed the spin-off of its cloud business, establishing ChronoScale as an independent publicly traded company. ChronoScale will trade on NASDAQ, with Applied Digital holding 97% of the shares. This move aims to enhance capital acquisition capabilities and business expansion, driving stock price volatility.
</li>
<li>
On May 4, Applied Digital announced it secured $300 million in senior secured transitional financing led by Goldman Sachs to support the construction of its third AI data center in North Dakota. The financing news boosted market confidence, leading to a rise in stock price.
</li>
<li>
On May 5, analyst Michael Grondahl maintained a buy rating on Applied Digital, setting a target price of $56. The analyst's optimistic outlook supports the stock price. Demand for AI data centers is growing, and the industry outlook is positive.
</li>
</ol>
Atlassian is up 3.47% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 4, Atlassian reported revenue growth of 32% year-over-year, exceeding market expectations, which drove the stock price up 29% in a single day. The earnings report shows that AI initiatives are gradually taking effect, and market pessimism has been overdone, leading to a reversal in investor sentiment. Source: Atlassian
</li>
<li>
On May 5, Zhitong Finance reported that the AI transformation poses challenges to the SaaS industry, with increased risks of market capitalization shrinkage for some companies. Atlassian is actively advancing the deployment of AI tools, and its stock price has fallen nearly 60% over the past year. Source: Zhitong Finance
</li>
<li>
On May 7, Barclays analysts maintained a buy rating on Atlassian with a target price of $112. Analysts are focusing on the technology sector, believing Atlassian has long-term growth potential. Source: Barclays AI transformation accelerates, and the SaaS industry faces challenges.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Global Engine is up 96.48% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news
Agilon Health is up 49.62% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 6, Agilon Health reported a net income of $49 million for the first quarter, far exceeding market expectations of $11.6 million. This financial performance significantly boosted investor confidence, driving the stock price up. Source: Reuters
</li>
<li>
On May 4, JP Morgan downgraded Agilon Health to &#34;Underweight&#34; with a target price of $21 due to persistently high medical utilization rates and ongoing execution risks. This rating adjustment led to a brief decline in stock price. Source: Reuters
On May 7, agilon health's stock price closed at $27.85, with analysts holding a &#34;hold&#34; rating, believing that the stock price will maintain range fluctuations in the short term. Source: MarketBeat The healthcare industry is facing high cost pressures and requires attention.
</li>
</ol>
Atara Biotherapeutics pre-market rose 46.04%. Based on recent key news:
<ol>
<li>
On May 7, Atara Biotherapeutics announced that the FDA agreed that its single-arm study could support future TAB-CEL market applications. This news significantly boosted the stock price, as the market holds an optimistic view on the regulatory prospects of its products. Source: Reuters
</li>
<li>
On May 6, Atara Biotherapeutics is about to announce its Q1 2026 financial report, with market expectations of revenue at $2.9 million and earnings per share at -$0.33. Despite the expected loss, investors maintain a positive outlook on its future development. Source: FactSet
</li>
<li>
On May 7, Atara Biotherapeutics had a positive outcome from its meeting with the FDA, planning to provide further regulatory updates in the third quarter. This move has strengthened market confidence in the approval of its products. Source: SEC Filing The biotech industry has seen frequent regulatory dynamics recently, and investors need to pay attention
</li>
</ol>

APLD

TEAM

Applied Digital pre-market down 3.57%; Atlassian pre-market up 3.47%; Global Engine pre-market up 96.48%; agilon health pre-market up 49.62%; Atara Biotherapeutics pre-market up 46.04%

Price Alert

Applied Digital

Pre-market hot trades in US stocks: Applied Digital pre-market down 3.57%; Atlassian pre-market up 3.47%